On January 28, 2026, CalciMedica, Inc. announced the discontinuation of its Phase 2 KOURAGE clinical trial for Auxora, following safety concerns raised by the Independent Data Monitoring Committee. The trial was halted for a reevaluation of study design and patient enrollment criteria, though no deaths related to the study drug were reported.